Viridian Therapeutics Inc
NASDAQ:VRDN

Watchlist Manager
Viridian Therapeutics Inc Logo
Viridian Therapeutics Inc
NASDAQ:VRDN
Watchlist
Price: 20.2 USD 2.96% Market Closed
Market Cap: 1.5B USD
Have any thoughts about
Viridian Therapeutics Inc?
Write Note

Intrinsic Value

VRDN's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one VRDN stock under the Base Case scenario is 7.68 USD. Compared to the current market price of 20.2 USD, Viridian Therapeutics Inc is Overvalued by 62%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

VRDN Intrinsic Value
7.68 USD
Overvaluation 62%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Viridian Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for VRDN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about VRDN?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Viridian Therapeutics Inc

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Viridian Therapeutics Inc

Provide an overview of the primary business activities
of Viridian Therapeutics Inc.

What unique competitive advantages
does Viridian Therapeutics Inc hold over its rivals?

What risks and challenges
does Viridian Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Viridian Therapeutics Inc recently?

Summarize the latest earnings call
of Viridian Therapeutics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Viridian Therapeutics Inc.

Provide P/S
for Viridian Therapeutics Inc.

Provide P/E
for Viridian Therapeutics Inc.

Provide P/OCF
for Viridian Therapeutics Inc.

Provide P/FCFE
for Viridian Therapeutics Inc.

Provide P/B
for Viridian Therapeutics Inc.

Provide EV/S
for Viridian Therapeutics Inc.

Provide EV/GP
for Viridian Therapeutics Inc.

Provide EV/EBITDA
for Viridian Therapeutics Inc.

Provide EV/EBIT
for Viridian Therapeutics Inc.

Provide EV/OCF
for Viridian Therapeutics Inc.

Provide EV/FCFF
for Viridian Therapeutics Inc.

Provide EV/IC
for Viridian Therapeutics Inc.

Show me price targets
for Viridian Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Viridian Therapeutics Inc?

How accurate were the past Revenue estimates
for Viridian Therapeutics Inc?

What are the Net Income projections
for Viridian Therapeutics Inc?

How accurate were the past Net Income estimates
for Viridian Therapeutics Inc?

What are the EPS projections
for Viridian Therapeutics Inc?

How accurate were the past EPS estimates
for Viridian Therapeutics Inc?

What are the EBIT projections
for Viridian Therapeutics Inc?

How accurate were the past EBIT estimates
for Viridian Therapeutics Inc?

Compare the revenue forecasts
for Viridian Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Viridian Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Viridian Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Viridian Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Viridian Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Viridian Therapeutics Inc with its peers.

Analyze the financial leverage
of Viridian Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Viridian Therapeutics Inc.

Provide ROE
for Viridian Therapeutics Inc.

Provide ROA
for Viridian Therapeutics Inc.

Provide ROIC
for Viridian Therapeutics Inc.

Provide ROCE
for Viridian Therapeutics Inc.

Provide Gross Margin
for Viridian Therapeutics Inc.

Provide Operating Margin
for Viridian Therapeutics Inc.

Provide Net Margin
for Viridian Therapeutics Inc.

Provide FCF Margin
for Viridian Therapeutics Inc.

Show all solvency ratios
for Viridian Therapeutics Inc.

Provide D/E Ratio
for Viridian Therapeutics Inc.

Provide D/A Ratio
for Viridian Therapeutics Inc.

Provide Interest Coverage Ratio
for Viridian Therapeutics Inc.

Provide Altman Z-Score Ratio
for Viridian Therapeutics Inc.

Provide Quick Ratio
for Viridian Therapeutics Inc.

Provide Current Ratio
for Viridian Therapeutics Inc.

Provide Cash Ratio
for Viridian Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Viridian Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Viridian Therapeutics Inc?

What is the current Free Cash Flow
of Viridian Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Viridian Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Viridian Therapeutics Inc

Current Assets 767.4m
Cash & Short-Term Investments 753.2m
Receivables 14k
Other Current Assets 14.1m
Non-Current Assets 4.5m
PP&E 3.7m
Other Non-Current Assets 853k
Current Liabilities 41.4m
Accounts Payable 6.3m
Accrued Liabilities 34.7m
Other Current Liabilities 288k
Non-Current Liabilities 23m
Long-Term Debt 20.5m
Other Non-Current Liabilities 2.5m
Efficiency

Earnings Waterfall
Viridian Therapeutics Inc

Revenue
302k USD
Operating Expenses
-283.3m USD
Operating Income
-283m USD
Other Expenses
26m USD
Net Income
-257.1m USD

Free Cash Flow Analysis
Viridian Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

Viridian Therapeutics has made significant progress in 2024, completing enrollment for its THRIVE Phase III trial with 113 patients, ahead of the target of 90. THRIVE aims to evaluate the drug 001 for active thyroid eye disease (TED) with top results expected by September 2024. The company maintains a strong financial position with $613 million in cash, securing its operational runway till the second half of 2026. Additionally, the subcutaneous drug 003 looks promising, with pivotal trials set to begin mid-year. Viridian’s strategy focuses on engineering advanced therapeutics to address unmet medical needs efficiently.

What is Earnings Call?
Fundamental Scores

VRDN Profitability Score
Profitability Due Diligence

Viridian Therapeutics Inc's profitability score is 22/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
ROE is Increasing
ROIC is Increasing
Negative 1-Year Revenue Growth
22/100
Profitability
Score

Viridian Therapeutics Inc's profitability score is 22/100. The higher the profitability score, the more profitable the company is.

VRDN Solvency Score
Solvency Due Diligence

Viridian Therapeutics Inc's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Negative Net Debt
75/100
Solvency
Score

Viridian Therapeutics Inc's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

VRDN Price Targets Summary
Viridian Therapeutics Inc

Wall Street analysts forecast VRDN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for VRDN is 41.44 USD with a low forecast of 22.22 USD and a high forecast of 64.05 USD.

Lowest
Price Target
22.22 USD
10% Upside
Average
Price Target
41.44 USD
105% Upside
Highest
Price Target
64.05 USD
217% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for VRDN?

Click here to dive deeper.

Dividends

Viridian Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for VRDN is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

VRDN Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

VRDN News

Other Videos

Profile

Viridian Therapeutics Inc Logo
Viridian Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

1.6B USD

Dividend Yield

0%

Description

Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. The company is headquartered in Waltham, Massachusetts and currently employs 86 full-time employees. The company went IPO on 2014-06-18. The firm is engaged in developing three product candidates, VRDN-001, VRDN-002, and VRDN-003, that is developed for intravenous (IV) or subcutaneous administration to treat patients who suffer from thyroid eye disease (TED). Its lead product candidate, VRDN-001, is a differentiated humanized monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially validated target for the TED. The company has initiated a Phase I/II clinical trial of VRDN-001. Its second product candidate, VRDN-002, is a distinct IGF-1R antibody that incorporates half-life extension technology, and is designed to support administration as a convenient, low volume, subcutaneous injection to treat patients who suffer from TED. VRDN-003 is an anti-IGF-1R monoclonal antibody with the same amino acid sequence as VRDN-001.

Contact

MASSACHUSETTS
Waltham
203 Crescent Street, Bldg. 17, Suite 102B
+16172724600
www.viridiantherapeutics.com

IPO

2014-06-18

Employees

86

Officers

CEO, President & Director
Mr. Stephen F. Mahoney J.D., MBA
Senior VP of Finance and Accounting, Principal Financial & Accounting Officer
Mr. Seth Harmon
Chief Operating Officer
Mr. Thomas W. Beetham J.D., MBA
Co-Founder & Chairman of Scientific Advisory Board
Dr. Eric N. Olson Ph.D.
Co-Founder & Member of the Scientific Advisory Board
Dr. Michael R. Bristow M.D., Ph.D.
Co-Founder & Scientific Advisory Board Member
Dr. Marvin H. Caruthers Ph.D.
Show More
Co-Founder & Scientific Advisor
Mr. Vahe Bedian Ph.D.
Chief Legal Officer
Ms. Jennifer Tousignant J.D.
Vice President of Investor Relations & Corporate Communications
Mr. John A. Jordan
Chief Human Resources Officer
Ms. Melissa Manno
Show Less

See Also

Discover More
What is the Intrinsic Value of one VRDN stock?

The intrinsic value of one VRDN stock under the Base Case scenario is 7.68 USD.

Is VRDN stock undervalued or overvalued?

Compared to the current market price of 20.2 USD, Viridian Therapeutics Inc is Overvalued by 62%.

Back to Top